Abstract:Cantharidin (CTD) is the major component of anticancer drugs obtained from Mylabris Cichorii and has a good inhibitory effect on several cancers, including hepatocellular carcinoma (HCC) and breast cancer. However, due to its toxicity, oral administration can cause various adverse reactions, limiting its clinical application. The aim of this work was to design glycyrrhetinic acid (GA)- and/or folate (FA)-modified solid lipid nanoparticles (SLNs) for the encapsulation of CTD to target HCC. Four CTD-loaded SLNs (cantharidin solid lipid nanoparticles (CSLNs), glycyrrhetinic acid-modified cantharidin solid lipid nanoparticles (GA-CSLNs), folate-modified cantharidin solid lipid nanoparticles (FA-CSLNs), and glycyrrhetinic acid and folate-modified cantharidin solid lipid nanoparticles (GA-FA-CSLNs)) were prepared by the emulsion ultrasonic dispersion method, and their physicochemical parameters were determined (particle size and distribution, morphology, zeta-potential, entrapment efficiency, drug loading, and hemolysis). Additionally, the antitumor activities of the four SLNs were evaluated comprehensively by tests for cytotoxicity, cell migration, cell cycle, apoptosis, cellular uptake, competition suppression assay, and in vivo tumor suppression assay. Four SLNs showed spherical shapes and mean diameters in the range of 75–110 nm with size dispersion (PDI) within the range of 0.19–0.50 and zeta-potential approximately –10 mV. The entrapment efficiency of CTD in SLNs was higher than 95% for all tested formulations, and no hemolysis was observed. Compared to GA-CSLNs or CSLNs, GA-FA-CSLNs and FA-CSLNs showed stronger cytotoxicity on hepatocellular carcinoma cells (HepG2), and the cytotoxicity of GA-FA-CSLNs on hepatocyte cells (L-02) was remarkably reduced compared with other formulations. GA-FA-CSLNs and FA-CSLNs also increased the inhibition of HepG2 cell migration, and FA-CSLNs had the highest apoptosis rate. The cell cycle results indicated that HepG2 cells were arrested mainly in the S phase and G2/M phase. Analysis of competition inhibition experiments showed that GA and FA ligands had targeted effects on HepG2 cells. The in vivo tumor inhibition experiment showed that GA-FA-CSLNs and FA-CSLNs had excellent tumor inhibition ability—their tumor inhibition rates were 96.46% and 89.92%, respectively. Our results indicate that GA-FA-CSLNs and FA-CSLNs have a promising future in the therapeutic intervention of HCC.

Antitumor activities of novel glycyrrhetinic acid-modified lipogel hybrid system in vitro

A Glycyrrhetinic Acid-Modified Curcumin Supramolecular Hydrogel For Liver Tumor Targeting Therapy

Use of different ligand modification liposomes to evaluate the anti-liver tumor activity of cantharidin

Computer Simulation on Polymer Micelles Combined Administration of Gambogic Acid and Curcumin as a Novel Anti-Cancer Drug Carrier

Anti-tumor therapy of glycyrrhetinic acid targeted liposome co-delivery of doxorubicin and berberine for hepatocellular carcinoma

A Wogonin-Loaded Glycyrrhetinic Acid-Modified Liposome for Hepatic Targeting with Anti-Tumor Effects.

Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma

Synthesis, Characterization, and in Vitro Evaluation of Two Synergistic Anticancer Drug-Containing Hepatoma-Targeting Micelles Formed from Amphiphilic Random Copolymer

Antitumor Effects of Curcumin and Glycyrrhetinic Acid-Modified Curcumin-Loaded Cationic Liposome by Intratumoral Administration

Antitumor Activity of Thermosensitive Hydrogels Packaging Gambogic Acid Nanoparticles and Tumor-Penetrating Peptide Irgd Against Gastric Cancer

Biodistribution and Biocompatibility of Glycyrrhetinic Acid and Galactose-Modified Chitosan Nanoparticles As a Novel Targeting Vehicle for Hepatocellular Carcinoma

Preparation and pharmacokinetics of glycyrrhetinic acid and cell transmembrane peptides modified with liposomes for liver targeted-delivery

Synthesis of Glycyrrhetinic Acid-Modified Chitosan 5-Fluorouracil Nanoparticles and Its Inhibition of Liver Cancer Characteristics in Vitro and in Vivo

Glycyrrhetinic Acid-Conjugated Polymeric Prodrug Micelles Co-Delivered with Doxorubicin As Combination Therapy Treatment for Liver Cancer.

Preparation and in vitro Anti-tumor Effect of Glycyrrhetinic Acid-targeting Doxorubicin Liposome

Improving Anti-Cancer Potentiality and Bioavailability of Gallic Acid by Designing Polymeric Nanocomposite Formulation

Acid-sensitive Polymeric Vector Targeting to Hepatocarcinoma Cells Via Glycyrrhetinic Acid Receptor-Mediated Endocytosis

Development of glycyrrhetinic acid ligand-functionalized liposomes for targeting hepatocellular carcinoma: synthesis, preparation, characterization, and evaluation

Novel targeting liposomes with enhanced endosomal escape for co-delivery of doxorubicin and curcumin

A hybrid membrane coating nanodrug system against gastric cancer <i>via</i> the VEGFR2/STAT3 signaling pathway

Synthetic Glycopolypeptide Micelle for Targeted Drug Delivery to Hepatic Carcinoma